Want to see AU:RHY full AI Analyst Report?
RHY Stock Chart & Stats
AU$0.14
<AU$0.01(1.16%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(1.16%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.28
Previous CloseN/A
Volume786.78K
Average Volume (3M)462.98K
Market Cap
AU$33.86M
Enterprise ValueAU$37.54M
Total Cash (Recent Filing)AU$1.73M
Total Debt (Recent Filing)AU$262.44K
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding364,059,840
10 Day Avg. Volume510,821
30 Day Avg. Volume462,976
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)22.03
Price to Sales (P/S)4.56
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Screening Test & AlgorithmRhythm's core product is a blood-based colorectal cancer screening test combined with algorithmic analysis, which is a durable competitive asset. Noninvasive, lab-deliverable screening aligns with structural trends in population screening and can scale into healthcare systems once approvals and reimbursement are secured.
High Gross Margin PotentialThe company reports a high gross profit margin, suggesting attractive per-test economics typical of diagnostics. If test volumes scale, fixed costs dilute and gross margins can sustainably support operating leverage and profitability over the medium term.
Improving Free Cash Flow TrendAn improving free cash flow trend indicates progress toward cash generation despite current negatives. Sustained FCF improvement reduces future financing needs and supports reinvestment or commercialization activities as revenue ramps, an important transitional fundamental metric.
Bears Say
Sharp Revenue DeclineA recent 42.87% revenue decline signals weak commercialization traction and revenue volatility. Continued top-line deterioration undermines scale economics, increases per-unit cost burdens, and heightens the need for external funding to sustain R&D and market development.
Persistent Negative ProfitabilityThe company reports negative net margin and negative EBIT/EBITDA, indicating structural operating losses. Without sustained revenue growth and operating improvements, losses will persist, pressuring cash reserves and forcing financing that can dilute shareholders or constrain strategic options.
Elevated LeverageA debt-to-equity ratio of 1.68 reflects elevated leverage for a pre-commercial diagnostic company. High leverage increases interest and refinancing risk, limits balance sheet flexibility during commercialization, and raises the probability of dilutive equity raises if operating cash flow stays negative.
Rhythm Biosciences Ltd. News
RHY FAQ
What was Rhythm Biosciences Ltd.’s price range in the past 12 months?
Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.
What is Rhythm Biosciences Ltd.’s market cap?
Rhythm Biosciences Ltd.’s market cap is AU$33.86M.
When is Rhythm Biosciences Ltd.’s upcoming earnings report date?
Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 50 days.
How were Rhythm Biosciences Ltd.’s earnings last quarter?
Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Rhythm Biosciences Ltd. overvalued?
According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued.
Does Rhythm Biosciences Ltd. pay dividends?
Rhythm Biosciences Ltd. does not currently pay dividends.
What is Rhythm Biosciences Ltd.’s EPS estimate?
Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rhythm Biosciences Ltd. have?
Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.
What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?
Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.
Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?
Currently, no hedge funds are holding shares in AU:RHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Biosciences Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
-476.27%
Trailing 12-Months
Asset Growth
-47.76%
Trailing 12-Months
Company Description
Rhythm Biosciences Ltd.
Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer. Established in 2017, the firm's main offices are located in Parkville, Australia.
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---